RT Journal Article
SR Electronic
T1 Interleukin-6, but not pentraxin 3, predicts adverse clinical outcomes on short-term prognosis of patients with incipient heart failure
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP p574
VO 38
IS Suppl 55
A1 Piera Boschetto
A1 Barbara Bottazzi
A1 Alessandro Fucili
A1 Alfredo Potena
A1 Licia Ballerin
A1 Mariarita Stendardo
A1 Simonetta Piva
A1 Alessia Verduri
A1 Bianca Beghé
A1 Alberto Mantovani
A1 Leonardo Fabbri
A1 Roberto Ferrari
A1 Claudio Ceconi
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/p574.abstract
AB We investigated the clinical significance of plasma interleukin (IL)-6, IL-1, IL-1 decoy receptor and pentraxin 3 (PTX3) levels in chronic heart failure (CHF) patients with or without chronic obstructive pulmonary disease (COPD). Plasma levels of these inflammatory markers were measured by using a sandwich enzyme-linked immunosorbent assay in 118 patients. Subjects were ≥65 years, ≥10 pack-years, with a new diagnosis of CHF. The prevalence of COPD was 30% (36/118). Only 2/118 patients had previously diagnosed COPD. The percent of patients given β-blockers (80% vs 89%, P = 0.1), and the optimized to CHF target dose of β-blockers (46.3% vs 59.7%, P = 0.1) were no different in patients with or without COPD. Subjects were prospectively followed for 357 (336-364) days with the end point of death or all-cause hospitalization (adverse event). Baseline plasma levels of IL-6, IL-1, IL-1 decoy receptor and PTX3 were comparable between CHF patients with and without COPD. None of the inflammatory markers correlated with CHF severity. Death or hospitalization occurred in 70 (59.3%) patients. High IL-6 levels was a significant independent predictor for adverse event (WALD CHI-SQUARE P=0.0083), whereas IL-1, IL-1 decoy receptor and PTX3 were not. IL-6 levels correlated positively with high-sensitive C-reactive protein (hs-CRP) levels (r = 0.67, p < 0.0001), although hs-CRP was not associated with death or hospitalization.These results suggest that plasma levels of IL-6 might serve as a prognostic markers in short-term prognosis of elderly CHF patients either with or without COPD.